VRTX - Alexion's Complementary Growth Strategy
Introduction - good things may be happening here
I stopped trading or commenting on Alexion (ALXN) in the first half of 2017, when there were countless uncertainties. ALXN was around $110 and was sold at a small loss. ALXN closed Wednesday at $125.18, lagging the market (SPY) and a major biotech ETF (IBB) over the past two years. That underperformance may reflect prior overvaluation. It also may reflect overcompensation for overestimating ALXN's values and virtues in the heat of what was, in 2015, the topping of a raging multi-year